arrow
B

Bruno Bockorny

Beth Israel Deaconess Medical Center
H指数:18
被引数:2,184

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial

Linavonkibart和pembrolizumab在免疫检查点阻断耐药的晚期实体瘤中的应用: 1期试验

2026-01-130
OAAI
First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain-Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors
2024-12-310
OAAI
A large-scale proteomics resource of circulating extracellular vesicles for biomarker discovery in pancreatic cancer

用于胰腺癌生物标志物发现的循环细胞外囊泡的大规模蛋白质组学资源

2024-12-180
OA
An open label, phase II trial of ERK inhibition alone and in combination with autophagy inhibition in patients with metastatic cancreatic cancer
2024-09-150
PRE
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
2024-06-1310
OAAI
NCI10217: Phase Ib biomarker-driven tumor-agnostic combination (Combo) trial of copanlisib (Copa) and olaparib (Ola) in molecularly-selected patients (pts) with advanced cancers with PIK3CA hotspot, PTEN and DNA damage response (DDR) mutations
2024-04-050
PRE
Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)
2023-06-0110
OA
SRK-181, A LATENT TGFb1 INHIBITOR: SAFETY, EFFICACY, AND BIOMARKER RESULTS FROM THE DOSE ESCALATION PORTION OF A PHASE I TRIAL (DRAGON TRIAL) IN PATIENTS WITH ADVANCED SOLID TUMORS
2022-11-071
OA
Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer

类器官敏感性与胰腺癌患者的治疗反应相关

2021-11-1764
OA
Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
2021-07-1241
OA
PDX-derived organoids model in vivo drug response and secrete biomarkers
2020-11-0581
OA